Expert opinion statement on the use of insulin therapy in patients with type 2 diabetes in primary care

Practical Diabetes International

Volumn 20, Issue 3, 2003, Pages 97-102

  Barnett, Anthony H ^a   Capaldi, Brenda ^b   Davis Lyons, Marie ^c   Farooqi, Azhar ^d   Gadsby, Roger ^e   Gilroy, Julia ^f   Hill, Jillian ^a   Hughes, Eugene ^g   Kirby, Mike ^h   Owens, David ⁱ   Tasker, Peter R W ^j   Vora, Jiten ^k  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f Primary Care Diabetes Specialist   (United Kingdom)

^g Ryde   (United Kingdom)

^h Hertfordshire Primary Care Research   (United Kingdom)

ⁱ LLANDOUGH HOSPITAL   (United Kingdom)

^j King's Lynn   (United Kingdom)

^k ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

Insulin therapy; Primary care; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT;

BOLUS INJECTION; CEREBROVASCULAR DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DOSE RESPONSE; DRUG INDICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HEALTH PRACTITIONER; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SKILL; SUPPORT GROUP; TITRIMETRY; UNITED KINGDOM; VASCULAR DISEASE; WEIGHT GAIN;

EID: 0037395642     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.457     Document Type: Review

References (25)

1. Department of Health. National Service Framework for Diabetes: Standards. London, UK: 2001.
2. UK Prospective Diabetes Study (UKPDS) Group. 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352:837-853.
3. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
4. Day C. The rising tide of type 2 diabetes. Br J Diabetes Vasc Dis 2001; 1: 37-43.
5. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997; 14(Suppl 5): S1S-S85.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-12.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986.
8. National Institute for Clinical Excellence. Inherited Clinical Guideline G. Management of Type 2 Diabetes - Management of Blood Glucose. London: NICE. 2002.
9. Winocour PH. Effective diabetes care: A need for realistic targets. BMJ 2002; 324: 1577-1580.
10. UK Prospective Diabetes Study (UKPDS) Group. 34. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes. Lancet 1998; 352: 854-865.
11. Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167.
12. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
13. Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23: 813-819.
14. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
15. Rosenstock J, Schwartz SL, Clark CM, Jr., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
16. Riddle MC, Rosenstock J, HOE901 4002 Study Group. Treatment to target study: Insulin Glargine vs NPH insulins added to oral therapy of type 2 diabetes: Successful control with less nocturnal hypoglycaemia. American Diabetes Association Annual Meeting 2002; San Francisco.
17. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-746.
18. Anderson JH, Jr., Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-270.
19. Brunelle BL, Llewelyn J, Anderson JH, Jr., et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726-1731.
20. Gale EA. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 200; 17: 209-214.
21. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000; 17: 762-770.
22. Meece JD, Campbell RK. Insulin lispro update. Diabetes Educ 2002; 28: 269-277.
23. National Institute for Clinical Excellence. Technology Appraisal Guidance - No.53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes - Insulin glargine. London: NICE, 2002.
24. Witthaus E, Stewart J, Bradley C. Improved Psychological Outcomes After Initiation of Insulin Treatment in Patients with Type II Diabetes. American Diabetes Association, 2000.
25. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001; 18: 619-625.